Hengrui Pharmaceutical announced that the first lockdown period of the company's 2025 A-share employee stock ownership plan will expire on November 7, 2026. The shareholding plan holds a total of 13.511,000 shares of the company, which are unlocked in three installments, with an initial unlocking ratio of 40%. According to the assessment, the company-level innovative drug revenue in 2025, the number of new molecular entities IND approved, and the number of innovative drug NDAs accepted all met 100% of the unlocking conditions; a total of 1,127 holders who met the unlocking conditions, corresponded to 4.713,700 unlockable stock shares, accounting for 0.07% of the company's total share capital. The Follow-up Management Committee will dispose of the relevant rights as agreed.

Hengrui Pharmaceutical announced that the first lockdown period of the company's 2025 A-share employee stock ownership plan will expire on November 7, 2026. The shareholding plan holds a total of 13.511,000 shares of the company, which are unlocked in three installments, with an initial unlocking ratio of 40%. According to the assessment, the company-level innovative drug revenue in 2025, the number of new molecular entities IND approved, and the number of innovative drug NDAs accepted all met 100% of the unlocking conditions; a total of 1,127 holders who met the unlocking conditions, corresponded to 4.713,700 unlockable stock shares, accounting for 0.07% of the company's total share capital. The Follow-up Management Committee will dispose of the relevant rights as agreed.